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Abstract: Hepatocellular carcinoma is one of few cancer types that continues to grow in incidence
and mortality worldwide. With the alarming increase in diabetes and obesity rates, the higher rates
of hepatocellular carcinoma are a result of underlying non-alcoholic fatty liver disease. Many have
attributed disease progression to an excess consumption of fructose sugar. Fructose has known
toxic effects on the liver, including increased fatty acid production, increased oxidative stress,
and insulin resistance. These effects have been linked to non-alcoholic fatty liver (NAFLD) disease
and a progression to non-alcoholic steatohepatitis (NASH). While the literature suggests fructose
may enhance liver cancer progression, the precise mechanisms in which fructose induces tumor
formation remains largely unclear. In this review, we summarize the current understanding of
fructose metabolism in liver disease and liver tumor development. Furthermore, we consider the
latest knowledge of cancer cell metabolism and speculate on additional mechanisms of fructose
metabolism in hepatocellular carcinoma.
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1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cancer and second leading cause of
cancer-related deaths worldwide. East Asian countries suffer the greatest disease burden, with more
than 40 in 100,000 people affected per year. This is attributed to the regional endemic infections of the
hepatitis B virus (HBV) and hepatitis C virus (HCV) [1]. In the US, only 6 in 100,000 people are affected
by HCC [2]. However, the incidence rate in the US has tripled since the 1970s and the three-year
survival rate is less than 20% [1–3]. Additionally, unlike most other cancer types, mortality rates for
HCC have significantly increased over the past decade in the US, Australia, and in Northern/Central
Europe [4,5]. Therefore, HCC has become the fastest growing cause of cancer-related deaths.
The major risk factors for HCC are HBV/HCV infections, aflatoxins, alcoholic liver disease,
non-alcoholic fatty liver disease (NAFLD), and the inflammatory form of non-alcoholic steatohepatitis
(NASH). Most HCC cases present with underlying cirrhosis, often due to viral infection or alcohol
abuse. The epidemiology and associated risk factors of viral infection/alcoholic liver disease are
well understood. In comparison, the link between NAFLD and the increased HCC incidence is less
well described. Males and older individuals (>50 years) with NAFLD are at a greater risk of HCC
development [6]. African American and Hispanic individuals with NAFLD may also be at greater
risk of HCC. African Americans often present with more advanced stages of HCC and both African
Americans and Hispanics with HCC are more resistant to curative therapy [7].
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Current treatment options for HCC therapy include surgical resection, liver transplantation,
radiofrequency ablation (RFA), transarterial chemoembolization (TACE), or medical treatment with
sorafenib or regorafenib [8]. Early-stage HCC is usually treated via resection, liver transplantation,
or ablation; however, these methods often come with complications [8]. Recurrence of HCC is common
post-resection and post-transplantation and occurs between 25% and 75% and 10% and 20% of cases,
respectively [9–11]. TACE is suitable for intermediate-stage HCC or for multinodular lesions but may
cause complications, such as hepatic failure [8,12]. For advanced-stage HCC, only two therapies are
available and are used for palliative medical treatment. Sorafenib is a tyrosine kinase inhibitor that
targets pathways associated with tumor angiogenesis and proliferation [13]. Moreover, sorafenib is not
curative and if effective, may only increase survival by 6–12 months [14,15]. Regorafenib is a similar
multikinase inhibitor that is used as a second-line treatment after a failed response to sorafenib [16].
Most diagnoses of HCC occur at the advanced stage where curative treatments are ineffective [14].
Therefore, there is an urgent clinical need for improved treatment options for HCC.
The development and progression of HCC is highly complex; thus, a deeper understanding of
tumor pathogenesis will aid in future therapeutic advances. Recent research has investigated the role of
dietary fructose in NAFLD and HCC progression. Excess fructose consumption is well established as a
causative factor for developing insulin resistance and fatty liver, thus the rise in NAFLD/NASH cases
progressing to HCC in developed countries may be attributed to Westernized diets. However, clinical
evidence of fructose association with HCC is limited. This review will address fructose metabolism,
the effects on liver and NAFLD pathogenesis, and how the metabolic fate of fructose may affect
HCC development.
2. Metabolic Effects of Fructose in NAFLD Development
2.1. Glucose Versus Fructose Metabolism
The liver is the main metabolic hub for ingested carbohydrates and absorbs most of the circulating
glucose from the blood. Circulating glucose is absorbed by hepatocytes via the glucose transporter
type 2 (GLUT2) receptor. In the cytosol, glucokinase (GK) phosphorylates glucose to generate
glucose-6-phosphate (G6P), which will either be converted to glycogen for energy storage or proceed
through glycolysis for adenosine triphosphate (ATP) production [17,18]. G6P is also a precursor for
the pentose phosphate pathway (PPP), which produces NADPH (nicotinamide adenine dinucleotide
phosphate) and ribose-5-phosphate, a precursor for nucleotide synthesis [19]. Excess glucose may also
be used to generate acetyl-CoA through the citric acid cycle, which utilizes NADPH from the PPP to
produce fatty acids [18,19]. Glucose metabolism is tightly regulated by factors such as insulin and
glucagon during different nutritional states to maintain metabolic homeostasis. Insulin stimulates
insulin receptors IRS1/2 (insulin receptor substrate) to activate a signaling cascade that results in the
dephosphorylation of glycogen synthase (GS), thus, increasing glycogen synthesis and regulating
hepatic glucose production [19,20].
Fructose metabolism, however, has another fate within the liver. Fructose is absorbed principally
by two GLUT transporter members, GLUT2 and GLUT5 [21]. GLUT5 is primarily expressed in
intestinal epithelial cells where fructose is rapidly absorbed and diffused into intestinal capillaries for
delivery to the liver via the portal vein, where uptake in hepatocytes occurs through GLUT2 [21,22].
Unlike glucose, fructose metabolism is not regulated by circulating hormones or by negative-feedback
loops. Fructose metabolism bypasses the regulated enzymatic reactions involving GK in glycolysis
and is rapidly converted to fructose-1-phosphate (F1P) by ketohexokinase (KHK). Two isoforms of
KHK are involved in phosphorylating fructose. In the liver, KHK-C is highly active and rapidly
phosphorylates fructose into F1P [23,24]. The isoform KHK-A is ubiquitously expressed at low levels
and is much less effective at phosphorylating fructose than KHK-C [23,24]. The rapid conversion of
fructose in hepatocytes maintains the plasma gradient allowing for continuous fructose uptake in
hepatocytes through GLUT2 [25]. F1P is hydrolyzed into dihydroxyacetone phosphate (DHAP) and
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glyceraldehyde by aldolase B [26]. Both DHAP and glyceraldehyde may be converted by triokinase
to glyceraldehyde-3-phosphate (GA3P), which may be used for the glycolytic pathway to produce
pyruvate or lactate, or may be used for gluconeogenesis to produce G6P [27]. Additionally, DHAP may
be reduced to glycerol-3-phosphate to be a mainstay for de novo lipogenesis (DNL), allowing the
synthesis of triglycerides (TG) and lipoproteins [27]. The basic metabolic differences in glucose and
fructose metabolism have been well summarized previously (Figure 1) [28,29].
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triglycerides and VLDL lipoproteins. ACC, acetyl-CoA carboxylase; ACL, ATP citrate lyase; ADP, 
adenosine diphosphate; ATP, adenosine triphosphate; FAS, fatty acid synthase; Glut2/5, glucose 
transporter 2/5; GS, glycogen synthase; GP, glycogen phosphorylase; TCA, citric acid cycle; VLDL, 
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pyruvate. Fructose can be transported through Glut2 or Glut5 and is metabolized into trioses
through the ATP-dependent enzyme, etoh xokinase-C. Glyceraldehy e and dihydr xyacetone
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The rapid conversion of fructose into trioses may overstimulate the production of triglycerides and
VLDL lipoproteins. ACC, acetyl-CoA carboxylase; ACL, ATP citrate lyase; ADP, adenosine diphosphate;
ATP, adenosine triphosphate; FAS, fatty acid synthase; Glut2/5, glucose transporter 2/5; GS, glycogen
synthase; GP, glycogen phosphorylase; TCA, citric acid cycle; VLDL, very low-density lipoprotein.
2.2. Fructose and Insulin Resistance
Fructose has been shown to increase the activity of proteins involved in lipogenesis,
gluconeogenesis, and glycolysis. Transcription factors carbohydrate-responsive element-binding
protein (ChREBP) and sterol regulatory element binding protein-1 (SREBP-1) are potent inducers of
lipogenesis by activatin genes such as fatty acid synthase (FAS) and acetyl coA carboxylase (ACC) [25],
and have been demonstrated to have increased activity in response to fructose feedi g [30–33].
Additionally, fructose increas s the expression of the gluconeogenic e zym s glucose-6-phosphatase
(G6Pase) nd fructos 1,6-biphosphatase 1 (FBP1), the glycolytic enzym s phosphofructokinase 1
(PFK1) and pyruvat kinase (PK), and increases glycogen and hepatic gluco e production [32,33].
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Therefore, it can be concluded that fructose increases the expression of genes that allow the conversion
of fructose-derived ketoses into glucose or to pyruvate for endogenous glucose and TG synthesis,
while inhibiting exogenous glucose uptake. Research also suggests that the regulation of these genes is
mediated by the fructose-induced activity of ChREBP and that this activity dominates the suppressive
effects of insulin on gluconeogenesis [25,33]. Therefore, the gluconeogenic and lipogenic action of
fructose, irrespective of insulin signaling, may contribute to hepatic insulin resistance. Furthermore,
some studies have demonstrated that a high fructose diet can reduce the phosphorylation of IRS1 and
expression of IRS2 [34–36]. However, more research is required to verify potential direct or indirect
effects of fructose on insulin receptor activity.
2.3. Fructose and Oxidative Stress
Fructose conversion to F1P occurs rapidly and is ATP-dependent, thus the ingestion of
fructose results in ATP and intracellular phosphate depletion and increased intracellular adenosine
monophosphate (AMP) [37,38]. Consequently, the activation of AMP deaminase occurs to stimulate
nucleotide degradation, converting AMP to inosine monophosphate (IMP) in an attempt to restore
phosphate and ATP levels, and results in the accumulation of uric acid as a by-product [39].
Intracellular uric acid causes mitochondrial oxidative stress, production of reactive oxygen species
(ROS), and increases hepatic fat accumulation [40]. Increased mitochondrial oxidative stress inhibits
enzymes involved in citrate metabolism [40], and accordingly mitochondrial citrate accumulates and
is released into the hepatocyte cytosol where it activates ATP-citrate lyase and FAS, and increases
hepatic DNL [40]. Additionally, uric acid causes endoplasmic reticulum stress, which also stimulates
the expression of lipogenic enzymes such as ACC and FAS through increased SREPB-1 signaling [41].
Increased TG synthesis in the liver overloads the ER with lipids for very low-density lipoprotein
(VLDL) synthesis, further promoting ER stress [42]. Hepatocyte release of uric acid into the circulation
may also cause adipocyte uptake of uric acid and induce the activation of NADPH oxidase to generate
ROS and oxidative stress in adipocytes [43]. The effects of uric acid on oxidative stress may occur
independently of fructose and excess caloric intake [40,41,43]. In addition, circulating uric acid may
promote insulin resistance in liver, fat, and muscle tissue by increasing serine phosphorylation of
IRS1 and inhibiting insulin responses [44]. Thus, through rapid deletion of ATP, and the subsequent
generation of uric acid, both hepatocytes and adipocytes are exposed to high levels or ROS that may
contribute to DNL, insulin resistance, and NAFLD (Figure 2).
2.4. Fructose, Inflammation, and NASH
The potential mechanisms of fatty liver development discussed above may also contribute to
hepatic inflammation and consequently a progression to NASH. Fructose-induced accumulation of uric
acid generates ROS both in hepatocytes and adipocytes (Figure 2), which induces a pro-inflammatory
signaling cascade through the release of cytokines [45]. Xanthine oxidase (XO) catalyzes the reaction
converting xanthine into uric acid, thus fructose-induced accumulation of uric acid follows an increase
in XO activity [46]. XO acts as an electron donor for oxygen, thus generating ROS and inducing
oxidative stress in liver [46,47]. Furthermore, uric acid directly activates the inflammasome NLRP3
(NLR family pyrin domain containing 3), which is responsible for the maturation of IL-1/18 (interleukin
1/18) [46,48–50]. The activation of NLRP3 is a significant step in the progression of NAFLD to
fibrosis and NASH as it activates immune system modulators responsible for stimulating fibrosis
and inflammation [51–53]. Continuous stimulation of fibrotic and chronic inflammation damages
hepatocytes and may lead to cirrhosis and HCC.
Furthermore, the cascade of inflammatory pathways induced by excess fructose consumption may
also contribute to the activation of stress hormones involved in the hypothalamus–pituitary–adrenal
(HPA) axis. In response to the fructose-induced inflammation in hepatocytes and adipocytes, the HPA
axis is activated to synthesize immunosuppressors, such as glucocorticoids [54,55]. This in turn
increases the activity of 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1), an important enzyme
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that activates glucocorticoids, such as cortisol, and is largely involved in metabolic-related diseases [56].
Increased bioactivity of cortisol may stimulate lipogenesis and lead to visceral fat deposition and
hepatic fat deposition [54,55,57]. Therefore, a fructose-induced disruption of the regulation of stress
hormones could in part contribute to NAFLD and NASH.
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Figure 2. Fructose and liver disease pathogenesis. Fructose sugar is rapidly metabolized by the liver
and causes a depletion of ATP, and results in uric acid accumulation. Uric acid causes metabolic
stress on liver organelles, such as the mitochondria, leading to increased citrate production and
lipogenesis. Uric acid may also circulate to the adipose tissue and cause adipocyte dysfunction and
inflammation, increasing circulating free fatty acids that may in turn contribute to fat deposition
within the liver. Uric acid also increases reactive oxygen species, leading to liver inflammation.
Fructose metabolism may additionally induce insulin resistance through inhibiting glucose uptake
and stimulating gluconeogenesis. AMP, adenosine monophosphate; ER, endoplasmic reticulum; FFA,
free fatty acids; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; ROS,
reactive oxygen species.
2.5. Fructose and the Microbiome
It has been well established through several animal and human studies that small intestine
microbiome dysbiosis is associated with NAFLD/NASH development, as demonstrated by increased
endotoxin levels and intestinal permeability [58]. Although the precise mechanisms have yet to
be elucidated, studies have shown that fructose consumption can elevate endotoxin translocation
from the gut to the liver [59–63]. This is likely due to the fact that fructose feeding is associated
with a loss of epithelial cell tight junctions, such as occludin and claudin-1, allowing endotoxins to
enter the liver and stimulate inflammatory reactions that could in turn contribute to NASH [64–66].
Furthermore, the abundance and diversity of intestinal flora may be altered due to excess fructose
exposure. Studies have described the effects of both high fructose and high fat diets on the relative
ratio of Firmicutes/Bacteroidetes, where in diets high in fructose or states of metabolic disorder, there is
a decrease in the relative abundance of Bacteriodes [59,66–68], which usually dominate the intestinal
tract in a healthy individual [69]. Of note, research has shown that the addition of some probiotics, such
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as strains of Lactobacillus, have protective effects and may restore the gut function after high fructose
exposure by increasing the levels of beneficial bacteria and restoring the intestinal barrier [64,70,71].
Nevertheless, due to the effects of fructose, sugar and Westernized diets have become an emerging
topic in health and metabolic-related diseases. This is still a complex field of study that requires further
investigation, especially as it pertains to the development of chronic liver conditions, such as NASH.
Moreover, due to the high dietary levels of fructose in these studies, whether the findings are relevant
to the human condition is questionable.
3. Clinical Observations of Fructose Metabolism in NAFLD
3.1. Epidemiological Association of Fructose and NAFLD
Current epidemiological studies show that the percentage of obese patients with NAFLD ranges
from 30% to 75%, whereas NAFLD in non-obese patients shows a surprisingly high range of 5%–30%.
The prevalence of NAFLD in the population varies substantially not only due to ethnical and
environmental differences, but also due to the poor accuracy of ultrasounds while they are the most
used method of diagnosing liver steatosis. Lean NAFLD cases have been characterized by visceral
obesity and low or even absent hepatic insulin resistance (IR) [72]. The development of NAFLD in lean
subjects may be attributed to adipose IR and visceral obesity even though hepatic IR remains normal,
causing an increased release of free fatty acids (FFA) from visceral fat, and the deposition of fats within
the liver due to drainage into the portal circulation [72,73].
While the precise mechanisms in which NAFLD develops in non-obese patients has yet to be fully
elucidated, dietary factors are likely to be a major contributor. One study has shown non-obese NAFLD
patients to consume more than double the amount of sugar per day than the matched healthy controls,
where nearly half of this sugar came from soft drinks [74]. Additionally, this study shows the overall
caloric intake and macromolecule diet composition to be similar in both groups, demonstrating that
excess consumption of high fructose soft drinks was the only independent variable associated with fatty
liver diagnosis [74]. Another study shows similar results in obese patients with and without metabolic
syndrome, where the excess sugar consumption was significantly higher in both groups compared to
the healthy controls [75]. Excess soft drink consumption was the strongest predictor of fatty liver in
these patient groups, irrespective of the diagnosis of metabolic syndrome [75]. Moreover, additional
reports have predicted that lean individuals that consume diets higher in fructose are believed to be
more likely to develop fatty liver, even when caloric intake is within normal range [72–74].
3.2. Fructose Metabolism in Humans is Variable
Some studies have shown small amounts of fructose in the presence of glucose can improve
glucose uptake and decrease hyperglycemia in normal and diabetic subjects, particularly in states of
exercise [76–79]. However, excess consumption of fructose may significantly reduce circulating insulin,
and possibly impair hepatic glucose metabolism [80–82]. Several short-term studies have shown that
fructose feeding, either in weight maintaining diets or hypercaloric diets, in healthy subjects may
increase intrahepatocellular lipids, DNL, and blood triglyceride levels [83–86]. Additionally, some of
these studies show that the consumption of fatty acids and coffee may attenuate the effects of very
low-density lipoprotein (VLDL) production induced by fructose consumption [85–87].
Other short-term investigations in obese children have shown that restricting fructose consumption
reduces liver fat, DNL, and improves insulin sensitivity [88,89]. In contrast, studies involving
fructose consumption in overweight/obese patients show that long-term or short-term consumption of
excess fructose or glucose made no difference in parameters of metabolic-related conditions, such as
inflammation, liver triglycerides levels, serum triglycerides, or insulin levels [90–92]. Furthermore,
one other long term study shows contradicting results, and it demonstrated that long term fructose
consumption could induce lipogenic and insulin resistance effects in obese patients [93]. Together,
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it is clear that there are contradicting pieces of evidence regarding the metabolic effects of fructose in
healthy versus overweight subjects.
However, considering that the majority of this clinical data was obtained over short time periods of
7–14 days, and the number of longer-term studies is limited, it remains unclear whether fructose alone
is solely responsible for changes in fat metabolism and insulin levels in patients. Furthermore, there is
a large range in the amount of fructose used in clinical studies varying from 20% to 35% of total energy
requirements, either as weight-maintaining diets or hypercaloric diets [83–85,90]. Interestingly, an
earlier evaluation of the estimated fructose consumption in the United States showed that the average
consumption of total fructose only represented between 8% and 12% of total energy. This equated to
approximately 1 gram/kilogram of body mass, whereas most clinical studies of fructose consumption
use diets containing approximately 3.5 grams/kilogram of body mass.
In healthy individuals, fructose circulates in the bloodstream at a significantly lower amount
of just 5.5 µM in the fasted state, as compared to 4.5 mM for circulating glucose [94]. However, on
ingestion, fructose levels rise many-fold more than those of glucose, increasing to nearly 300 uM and
remain elevated in the bloodstream for one to two hours longer than glucose [94]. Therefore, it is
unclear if the clinical studies using high fructose diets truly reflect what is normally consumed in the
Westernized diet, or if the extreme amounts of fructose used in these studies are the major reason for
causing lipogenic effects.
Several meta-analyses display this controversy by indicating the large number of heterogenic
studies that contribute to differences in fructose metabolism in healthy versus overweight patients.
By example, a meta-analysis revealed that isocaloric diets supplemented with fructose over glucose
showed no increase in postprandial triglycerides [95]. However, when the studies only investigating
overweight subjects were considered, fructose significantly increased triglycerides compared to the
supplementation with glucose [95]. In studies with hypercaloric diets, fructose supplementation
significantly increased postprandial triglycerides in both normal and overweight subjects [95].
In contrast to the above, another meta-analysis identified fructose feeding to be positively
associated with fasting blood sugar levels and increased triglycerides [96]. However, when the studies
that significantly contributed to study heterogeneity were eliminated, the association of fructose with
the symptoms of the metabolic syndrome were not statistically significant [96]. Another meta-analysis
showed fructose consumption to increase hepatic insulin resistance in isocaloric and hypercaloric
healthy non-diabetic subjects, but had no effect on extrahepatic insulin resistance [97]. It may therefore
be concluded that the effects of fructose on metabolism vary quite substantially, and likely contribute
to liver disease alongside other factors, such as body mass index (BMI), metabolic disorders, and other
dietary factors.
4. A challenging Theory—Does Fructose Contribute to HCC Development?
4.1. Association of Fructose Consumption and Cancer Risk
The progression of NASH to HCC is likely to be multifactorial, including factors such as oxidative
stress and chronic inflammation leading to damaged hepatocytes and the stimulation of fibrosis,
lipotoxicity, and genetic mutations. NASH is a major risk factor for HCC, with 4%–22% of HCC cases
relating to underlying NAFLD and NASH [98]. However, it remains unclear how fructose contributes
to HCC development. Studies have investigated the association of sugar consumption with general
cancer risk, but with varying associations based on the sugar and cancer type in question. Reports have
shown a positive association with sugar consumption, either as glucose, fructose, or sugar-sweetened
beverages, and pancreatic cancer [99–103]. However, some larger studies showed no association
with sugar consumption and an increased risk of cancer development [104–106]. Furthermore, two
NIH-American Association of Retired Persons (AARP) studies have shown that additive fructose has
limited association with overall cancer risk of the major cancer types or cancer-related mortality [107,108].
Specifically, fructose intake was weakly associated with a decreased risk for all cancers in men, and a
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decreased risk of liver and ovarian cancer in women [107]. For both sexes, fructose consumption only
associated with an increased risk of small intestine cancer [107]. However, a more recent study showed
no association with fructose intake and risk of cancer-related mortality in men or women [108].
Regarding HCC, there are limited studies that have investigated the relationship of fructose
consumption and HCC risk. Some studies have shown a positive association between glucose and
the risk of HCC, where a sample of 147 and 250 respective HBV/HCV HCC patients with a high
glycemic load had an increased overall risk (OR) of HCC compared to control (OR 3.25 and OR
1.95, respectively) [109,110]. Another study showed that in 191 HCC patients there was a positive
association with high total sugar intake and HCC (Hazard Ratio 1.88) [111]. However, the link between
fructose consumption and HCC remains poorly investigated, and the limited data that we present
below concerning the topic is controversial. Therefore, there is a need for future studies to determine
the associated risks of HCC with the consumption of diets high in fructose sugar.
4.2. Traditional Animal Models Suggest High Fructose Promotes HCC Development
Some animal studies have demonstrated that fructose containing diets increase the incidence
of liver tumor growth. In one study, using the carcinogen diethylnitrosamine (DEN), mouse HCC
was evaluated using diets that included (i) normal chow, (ii) high sucrose/high lard fat, (iii) high
sucrose/high coconut oil fat, (iv) high sucrose/fructose and low fat, and (v) and high lard/low sugar.
Healy and colleagues demonstrated a similar tumor incidence among male mice fed the above
diets [112]. However, the tumor burden was significantly increased in the high sucrose/high lard fat
and the high sucrose/fructose and low fat groups, compared to the high lard/low sugar and normal
chow diets. Histology demonstrated the high sucrose/high lard fat liver tumors to have 30% HCC
morphology compared to the high sucrose/fructose and low fat, which had only 10% HCC foci [112].
Thus, in this model the combination of a high carbohydrate and high fat diet contributed to HCC
development rather than high fructose alone.
It is known that males are at a greater risk of attaining HCC. Therefore, using the above models,
the same investigators observed that female mice had increased tumor incidence when fed the high
sucrose/high lard fat, and high sucrose/fructose and low fat diets, compared to the high lard/low sugar
and normal diets [113]. Interestingly, the tumor burden was highest in high sucrose/high lard fat diet
and the high sucrose/fructose and low fat diet. The high sucrose/high coconut fat diet had the lowest
tumor burden [113]. Similar to the male mice, in female mice the high sucrose and high fat was the
greatest contributor to tumor development, although high sucrose/fructose and low fat also increased
tumor growth compared to normal chow [113]. Taken together, sex appears to play a significant role in
the metabolic contributions of fructose to HCC development.
Another study evaluating DEN-treated rats on an eight-week diet of either high-fat, high-fructose,
or normal chow reported somewhat controversial results. In this study, pre-cancerous cells were more
prominent in the high-fructose compared to the high-fat diet [114]. Liver oil red O staining revealed the
high-fat diet to have significantly promoted more hepatic fat deposits compared to the high-fructose
diet, even though the liver weights remained similar between diet groups [114]. The short duration of
diet feeding and differences in diet composition likely caused these differences. Recently, a new murine
model of NASH-HCC has been developed that utilizes a combination of a diet high in fat and fructose
with chemical treatment of carbon tetrachloride (CCl4) to induce fatty liver, fibrosis, and HCC [115].
Collectively, these results suggest a combination of high fat and high fructose to be a promoter of
HCC development.
4.3. Genetic Changes Associated with HCC May Reduce Fructose Metabolism
While there is limiting clinical evidence regarding the genetic changes associated with fructose
exposure in HCC, there are several studies that imply reduced fructose metabolism in HCC. A recent
study has demonstrated this in vitro, evident by a metabolic switch from KHK-C expression to
predominant expression of KHK-A in HCC [116], which has a low affinity and metabolic flux for
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fructose. Additionally, the authors showed that KHK-A activates downstream enzymes involved in
activating the PPP, thus contributing to HCC development [116]. While this study confirmed that
liver cancer cells had significantly reduced fructose metabolism compared to normal hepatocytes,
the effects on cell proliferation were not evaluated. Similarly, another study showed that human HCC
tumors had reduced aldolase B expression compared to the paired non-cancerous tissue, and this was
associated with reduced survival [117,118]. Aldolase B overexpression can also decrease tumor cell
migration and inhibit HCC-related metastasis [118]. Studies have also investigated the role of FBP1
as a prognostic marker of HCC. FBP1 is a gluconeogenic enzyme that is upregulated in response to
fructose exposure [33]. Clinical research has shown that low FBP1 expression is associated with poorer
survival and more aggressive HCC growth [119–124]. Low FBP1 expression enhances glycolysis in
HCC [122,124], while increasing FBP1 reduced GLUT1 expression, glucose uptake, lactate production,
and cell growth [120,121,123]. KHK-C, aldolase B, and FBP1 all increase after fructose consumption
and are required for the breakdown of glycolytic products. Together, these data suggest that fructose is
poorly metabolized by HCC, or that it inhibits tumor cell growth in a glycolysis-dependent cell.
4.4. Fructose May Promote Metabolic Adaptations of the Traditional Warburg Effect
Tumor progression is dependent on acquired characteristics that allow the growth and development
of cancerous cells, commonly known as the hallmarks of cancer [125]. The hallmark that describes
the ability of cancer cells to reprogram energy metabolism is of interest to this review, in particular
glucose metabolism to favor the glycolytic pathway, otherwise known as the “Warburg effect” [126].
Otto Warburg first described the altered metabolism of cancer cells in 1930, where in aerobic conditions
cancer cells favor generating ATP and lactate from glycolysis. Later studies confirmed that this
caused the build-up of glycolytic metabolites that feed into the PPP to result in the generation
of more nucleotides, NADPH, and lipids for multiplying tumor cells [127–129]. Mechanistically,
the availability of growth factors and glucose will push cancer cells towards glycolysis for the purpose
of generating energy and biomolecules. Growth signals, such as epidermal growth factor receptor
(EGFR), activate the PI3K/Akt signaling pathway and consequently increase glucose transporters
(GLUT1) expression and the activity of PFK2 [130]. PFK2 phosphorylates fructose-6-phosphate (F6P)
to generate fructose-2,6-biphosphate (F-2,6-BP), which promotes glycolysis by activating PFK1 and in
turn inhibits gluconeogenesis through inhibiting FBP1 [130,131]. Hence, increased F-2,6-BP stimulates
cancer cell glycolysis to fuel cell growth. This state is also induced by high levels of glucose and insulin,
which may further induce F-2,6-BP production [132].
However, recently our understanding of cancer metabolism has shifted to a more dynamic
view. This is termed the “reverse Warburg effect”, whereby anabolic cancer cells metabolically
adapt to the tumor microenvironment and promote aerobic glycolysis in the neighboring stromal
cells. The stromal cells produce lactate, fatty acids, amino acids, glutamine, and ketone bodies
that are in turn used by the cancer cells to support growth [131,133–135]. In response to metabolic
stress, cancer cells may shift away from glycolysis and primarily utilize the PPP and mitochondrial
oxidative phosphorylation as the primary means of obtaining energy, producing nucleotide precursors,
and generating antioxidants to manage ROS. This switch is in part driven by the p53-induced
TP53-induced Glycolysis and Apoptosis Regulator (TIGAR), which has a similar function to that of
FBP1. TIGAR inhibits glycolysis by converting F-2,6-BP into F6P, which increases the flux of carbons
into the PPP to generate NADPH and nucleotides [136]. Importantly, an increased TIGAR expression
is associated with cancer cell growth and tumor progression [131,137–139]. TIGAR expression can also
induce monocarboxylate transporter (MCT) expression, allowing cancer cells to use catabolites from
the neighboring metabolically reprogrammed stromal cells. In this manner, the stromal cells increase
glycolysis to produce lactate, which is supplied to the growing cancer cells [135,140]. Cancer cells then
use the citric acid cycle to utilize uptake of lactate and other catabolic metabolites for the production of
energy and antioxidants [131,140,141]. Such compounds also include glutamine, which is metabolized
to glutamate to fuel the citric acid cycle through α-ketoglutarate [142,143], and the generation of
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glutathione (GSH), a potent antioxidant that detoxifies ROS and carcinogens that accumulate in active
and metabolically stressed cancer cells [144]. Significantly, increased GSH associates with elevated
HCC proliferation and growth [145,146] and contributes to chemo-resistance [147,148].
According to these authors, integrating these observations with the current knowledge on fructose
metabolism, results in a conflicting model of cancer development. The metabolic fate of fructose causes
rapid depletion of ATP levels, increased cellular ROS, and increased gluconeogenesis. It could be
expected that in HCC cancer cells that display the Warburg effect, a high fructose diet would not
supply cancer cells with the appropriate fuel. The rapid conversion to F1P would be deleterious to
proliferating cells due to ATP depletion, nucleotide degradation, and the accumulation of uric acid and
ROS. As the Warburg effect encourages glycolysis, we would not expect much fructose to enter the
PPP and promote nucleotide synthesis. It would be expected that the overload of ROS in association
with depleted energy and nucleotides would lead to apoptosis. Additionally, as discussed in previous
sections, the enzymes involved in fructose metabolism are thought to act as HCC tumor suppressors.
Thus, it is conceivable that while fructose may contribute to NAFLD pathogenesis, HCC fed by fructose
may lead to growth inhibition (Figure 3). Although, in the clinical setting this is not relevant as
fructose is not the sole energy source for the human diet. Nevertheless, knowledge of the biochemical
consequences of fructose metabolism in cancer cells is novel and warrants further investigation. It is
possible that such studies could reveal new ways to target cancer cell growth.
Taking into account the current evidence, we suggest that fructose consumption more likely
drives cancer cells into a metabolically stressed state, inducing the reverse Warburg effect to
maintain cell growth and control the increase in cellular ROS. This is exemplified by the fact that
fructose consumption has been shown to increase expression of FBP1 as well as increase enzymatic
activity of glucose-6-phosphate dehydrogenase (G6PD), a key enzyme in the PPP [33]. Furthermore,
fructose induces expression of ChREBP, which is a known activator of TIGAR [33,149]. Thus, it could
be concluded that cancer cells adapt to fructose-induced metabolic stress by increasing gluconeogenesis
and the PPP, increasing glutamine uptake to reduce ROS, and utilizing catabolites from the tumor
microenvironment (Figure 3). While the reverse Warburg effect supports this theory, more research is
required to confirm the action of fructose on promoting or inhibiting HCC metabolism. Such studies
also need to consider the relevancy of the human diet where glucose and fat consumption is the norm.
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Figure 3. Potential consequences of fructose metabolism in hepatocellular carcinoma (HCC).
A traditional HCC cancer cell may exhibit the Warburg effect where glycolysis is favored to produce
ATP and glycolytic products for nucleotide synthesis. If this cancer cell is exposed to fructose as the
only source of fuel, the toxic effects of fructose may be deleterious to the cell by depleting energy
and increasing ROS, leading to cell death. However, in cancer cells exposed to high concentrations of
fructose, the cancer cell ay etabolically adapt to sustain gro th through activation of the MCT and
gluconeogenic enzymes. In this case the cell switches to the ‘reverse Warburg effect’ to utilize fructose
by-products to fuel nucleotide synthesis and to uptake catabolites from neighbouring cells for production
of energy and antioxidants. ATP, adenosine triphosphate; AMP, adenosine monophosphate; DHAP,
dihydroxyacetone phosphate; F1P. P, fructose-1-phosphate; G6P, glucose-6-phosphate; Glut1, glucose
transporter 1; Glut2, glucose transporter 2; Glut5, glucose transporter 5; KHK-A, ketohexokinase-A;
KHK-C, ketohexokinase-C; MCT, monocarboxylate transporters; PPP, pentose phosphate pathway;
ROS, reactive oxygen species; SGS, serine to glycine synthesis pathway; TCA, tricarboxylic acid cycle
(citric acid cycle).
5. Conclusions
Fructose metab lism has been implic ted in the de el pment and progression of NAFLD and
NASH. Fructose metabolism in the liver bypasses the regulat ry enzymes of glycolysis and is believed
to result in increased lipogenes s, oxid tive stress, and inflammat on. Some studies have utilized
high-fructose diets to study HCC development; however, it remains unclear how these models
may translate to clinical NASH-HCC. O r curre t knowled e n traditional cancer metabolism and
the genetic changes associated with HCC suggest that fructose as a fuel source may restrict tumor
growth. However, while fructose may induce metabolic stress in cancer cells, it is likely that metabolic
reprogramming will occur to allow continued tumor growth. A better understanding of the role of
fructose in NAFLD-HCC development and the metabolic fates of fructose in cancer cells will allow
for more specific drug therapies to be developed. Targeted treatment options are required to more
effectively treat the increasing number of NAFLD-HCC cases arising in developed countries.
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